Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2014-09-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1404221111PMID 25201979PMCID PMC4183331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical Characterization of the Phosphatase Domain of the Tumor Suppressor PH Domain Leucine-Rich Repeat Protein Phosphatase

  2014cited by this paper
• Sensing core histone phosphorylation — A matter of perfect timing

  2014cited by this paper
• Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

  2014cited by this paper
• Pharmacological Inhibition of Pleckstrin Homology Domain Leucine-Rich Repeat Protein Phosphatase Is Neuroprotective: Differential Effects on Astrocytes

  2013cited by this paper
• WD Repeat Protein WDR48 in Complex with Deubiquitinase USP12 Suppresses Akt-dependent Cell Survival Signaling by Stabilizing PH Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1)*

  2013cited by this paper
• miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.

  2013cited by this paper
• Downregulation of PHLPP Expression Contributes to Hypoxia-Induced Resistance to Chemotherapy in Colon Cancer Cells

  2013cited by this paper
• Suppression of survival signalling pathways by the phosphatase PHLPP

  2013cited by this paper
• Histone phosphorylation

  2012cited by this paper
• The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

  2012cited by this paper
• Cancer epigenetics: from mechanism to therapy.

  2012cited by this paper
• Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase (PHLPP): A New Player in Cell Signaling*

  2011cited by this paper
• The biology of HDAC in cancer: the nuclear and epigenetic components.

  2011cited by this paper
• PHLPP-Mediated Dephosphorylation of S6K1 Inhibits Protein Translation and Cell Growth

  2011cited by this paper
• Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA

  2011cited by this paper
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

  2011cited by this paper
• A Peek into the Complex Realm of Histone Phosphorylation

  2011cited by this paper
• Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

  2011influential reference
• ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA

  2011cited by this paper
• Mislocalization of the E3 Ligase, β-Transducin Repeat-containing Protein 1 (β-TrCP1), in Glioblastoma Uncouples Negative Feedback between the Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1) and Akt*

  2011cited by this paper
• Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.

  2010cited by this paper
• Epigenetics in cancer.

  2010cited by this paper
• Discovery of Small Molecule Inhibitors of the PH Domain Leucine-Rich Repeat Protein Phosphatase (PHLPP) by Chemical and Virtual Screening

  2010cited by this paper
• Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

  2010cited by this paper
• Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis.

  2010cited by this paper
• Protein phosphatase PHLPP1 controls the light-induced resetting of the circadian clock

  2010cited by this paper
• Nuclear run-on assay.

  2009cited by this paper
• Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C*

  2009influential reference
• Loss of PHLPP expression in colon cancer: Role in proliferation and tumorigenesis

  2008cited by this paper
• Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation

  2008cited by this paper
• The Phosphatase PHLPP Controls the Cellular Levels of Protein Kinase C*

  2008influential reference
• Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

  2008cited by this paper
• Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.

  2008cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer

  2007cited by this paper
• Posttranscriptional Expression Regulation: What Determines Translation Rates?

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.

  2007cited by this paper
• PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• The EGF receptor family: spearheading a merger of signaling and therapeutics.

  2007cited by this paper
• Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.

  2006cited by this paper
• Chromosome 16 tumor‐suppressor genes in breast cancer

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.

  2006cited by this paper
• Inducible Covalent Posttranslational Modification of Histone H3

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

  2005influential reference
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005influential reference
• Image processing with ImageJ

  2004cited by this paper
• Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

  2003cited by this paper
• Targeting HER1/EGFR: a molecular approach to cancer therapy.

  2003cited by this paper
• Characterization of sporadic colon cancer by patterns of genomic instability.

  2003cited by this paper
• The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

  2003cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells

  2001cited by this paper
• Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

  2001cited by this paper
• The Phosphoinositide-dependent Kinase, PDK-1, Phosphorylates Conventional Protein Kinase C Isozymes by a Mechanism That Is Independent of Phosphoinositide 3-Kinase*

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The language of covalent histone modifications

  2000cited by this paper
• The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

  1998cited by this paper
• Signaling to chromatin through histone modifications: how clear is the signal?

  1998cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• Signaling by Receptor Tyrosine Kinases

  1993cited by this paper
• Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Cáncer

  1939cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• PHLPP: a Janus-faced regulator in oncogenesis.

  2025cites this paper
• Lipid–Protein Interplay in the Regulation of Receptor Tyrosine Kinases

  2025cites this paper
• Recent advances in PHLPP1 and PHLPP2 research: an update in the heart

  2025cites this paper
• PHLPP1 regulates region-specific astroglial mitochondrial fission in response to oxidative stress in the male rat hippocampus

  2025cites this paper
• Phosphatase PHLPP1 is an alveolar-macrophage-intrinsic transcriptional checkpoint controlling pulmonary fibrosis.

  2025cites this paper
• Phlpp1 alters the murine chondrocyte phospho-proteome during endochondral bone formation.

  2024cites this paper
• Emerging roles of PHLPP phosphatases in lung cancer

  2023cites this paper
• Characterizing crosstalk in epigenetic signaling to understand disease physiology.

  2023cites this paper
• PHLPP Signaling in Immune Cells.

  2022cites this paper
• Emerging roles of PHLPP phosphatases in the nervous system.

  2022cites this paper
• PHLPPs: emerging players in metabolic disorders.

  2022cites this paper
• The PHLPP1 N-Terminal Extension Is a Mitotic Cdk1 Substrate and Controls an Interactome Switch

  2021cites this paper
• PHLPPing the balance: restoration of protein kinase C in cancer.

  2021cites this paper
• Chondrocytic and pharmacokinetic properties of Phlpp inhibitors

  2021cites this paper
• On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.

  2021cites this paper
• Emerging roles of PHLPP phosphatases in metabolism

  2021cites this paper
• Myeloid Lineage Ablation of Phlpp1 Regulates M-CSF Signaling and Tempers Bone Resorption in Female Mice

  2021cites this paper
• PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling.

  2020cites this paper
• PH domain and leucine rich repeat phosphatase 1 (Phlpp1) suppresses parathyroid hormone receptor 1 (Pth1r) expression and signaling during bone growth

  2020influential citation
• Arecoline suppresses epithelial cell viability through the Akt/mTOR signaling pathway via upregulation of PHLPP2.

  2019cites this paper
• Myosin 1b Regulates Nuclear AKT Activation by Preventing Localization of PTEN in the Nucleus

  2019cites this paper
• Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice

  2019cites this paper
• PHLPP1 counter-regulates STAT1-mediated inflammatory signaling

  2019cites this paper
• Protein phosphatases in chromatin structure and function

  2019cites this paper
• Enhanced Neutrophil Immune Homeostasis Due to Deletion of PHLPP

  2019cites this paper
• PHLPP2 as a novel metastatic and prognostic biomarker in non‐small cell lung cancer patients

  2019cites this paper
• Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritis

  2018cites this paper
• Human colorectal cancer initiation is bidirectional, and cell growth, metabolic genes and transporter genes are early drivers of tumorigenesis.

  2018cites this paper
• High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma

  2017cites this paper
• PHLPP: a putative cellular target during insulin resistance and type 2 diabetes.

  2017cites this paper
• Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification.

  2017cites this paper
• P PH Domain Leucine-Rich Repeat Protein Phosphatase ( PHLPP )

  2017cites this paper
• miR‐181 elevates Akt signaling by co‐targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer

  2017cites this paper
• PHLPPing through history: a decade in the life of PHLPP phosphatases.

  2016cites this paper
• PHLPP phosphatases as a therapeutic target in insulin resistance-related diseases

  2016influential citation